BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact
BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.
Zacks · 1天前
How Biomarin Beat Expectations in Q2
You won't find many people who would complain about BioMarin Pharmaceutical's (NASDAQ: BMRN) performance so far this year. Here are the highlights from BioMarin's Q2 update. The company announced a net loss in the second quarter of $29.2 million, or $0.16 pe
Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. includin
Motley Fool · 1天前
BioMarin Pharmaceutical EPS misses by $0.04, beats on revenue, expects FY20 GAAP profit
BioMarin Pharmaceutical (NASDAQ:BMRN): Q2 GAAP EPS of -$0.16 misses by $0.04. Revenue of $429.5M (+10.8% Y/Y) beats by $12.1M. For the FY20, BioMarin conti
seekingalpha · 2天前
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 100.00% and 2.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per
Benzinga · 2天前
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)